The balance sheet is debt-free with a current ratio of 10.05 and equity of $1.7B, though cash has declined to $111.5M from $421.1M in Q2 2024, and goodwill of $91.6M warrants monitoring.
| Total Current Assets | 1.65B | 1.36B | 1.01B | 185.81M | 206M |
| Cash & Short-Term Investments | 1.25B | 1.19B | 914.3M | 149.31M | 163.14M |
| Cash Only | 111.45M | 167.61M | 79.55M | 45.1M | 76.09M |
| Short-Term Investments | 1.14B | 1.02B | 834.75M | 104.22M | 87.06M |
| Accounts Receivable | 192.47M | 83.2M | 38.81M | 8.34M | 10.72M |
| Days Sales Outstanding | 34.42 | 35.62 | 35.75 | 26.27 | 48.99 |
| Inventory | 113.78M | 58.98M | 43.22M | 24.09M | 28.87M |
| Days Inventory Outstanding | 86.87 | 103.86 | 168.54 | 244.52 | 497.33 |
| Other Current Assets | 92.69M | 31.03M | 16.65M | 686K | 509K |
| Total Non-Current Assets | 279.61M | 169.79M | 41.53M | 10.48M | 5.73M |
| Property, Plant & Equipment | 119.28M | 92.04M | 35.65M | 7.58M | 3.52M |
| Fixed Asset Turnover | 12.62x | 9.26x | 11.12x | 15.27x | 22.67x |
| Goodwill | 91.56M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 68.77M | 77.75M | 5.88M | 2.9M | 2.2M |
| Total Assets | 1.93B | 1.53B | 1.05B | 196.29M | 211.73M |
| Asset Turnover | 0.74x | 0.56x | 0.38x | 0.59x | 0.38x |
| Asset Growth % | 187.64% | 45.26% | 437.21% | -7.29% | - |
| Total Current Liabilities | 164.31M | 133.04M | 86.54M | 35.08M | 40.09M |
| Accounts Payable | 53.93M | 42.36M | 26.92M | 6.34M | 10.29M |
| Days Payables Outstanding | 54.31 | 74.6 | 104.98 | 64.31 | 177.32 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 15M | 0 | 0 |
| Other Current Liabilities | 85.8M | 90.68M | 37.92M | 11.66M | 9.71M |
| Current Ratio | 10.05x | 10.24x | 11.71x | 5.30x | 5.14x |
| Quick Ratio | 9.36x | 9.79x | 11.21x | 4.61x | 4.42x |
| Cash Conversion Cycle | 66.98 | 64.89 | 99.3 | 206.48 | 369 |
| Total Non-Current Liabilities | 41.49M | 35.15M | 3.17M | 3.79M | 256.93M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 98.18M | 35.15M | 0 | 778K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 41.49M | 0 | 3.17M | 3.01M | 256.93M |
| Total Liabilities | 205.8M | 168.19M | 89.71M | 38.87M | 297.02M |
| Total Debt | 0 | 35.15M | 1.29M | 2.93M | 1.6M |
| Net Debt | -111.45M | -132.46M | -78.27M | -42.16M | -74.49M |
| Debt / Equity | 0.00x | 0.03x | 0.00x | 0.02x | - |
| Debt / EBITDA | 0.00x | 0.19x | - | - | - |
| Net Debt / EBITDA | -0.39x | -0.73x | - | - | - |
| Interest Coverage | - | - | - | - | - |
| Total Equity | 1.73B | 1.36B | 964.8M | 157.43M | -85.29M |
| Equity Growth % | 179.67% | 41.34% | 512.86% | 284.57% | - |
| Book Value per Share | 9.47 | 7.59 | 7.35 | 1.03 | -0.65 |
| Total Shareholders' Equity | 1.73B | 1.36B | 964.8M | 157.43M | -85.29M |
| Common Stock | 17K | 17K | 16K | 4K | 4K |
| Retained Earnings | 243.74M | 10.34M | -208.8M | -125.38M | -99.12M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3.37M | 4.31M | 426K | 259K | -229K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Extreme valuation and insider selling
Astera Labs' equity surged to $1.7B in Q2 2026 from $808.8M in Q1 2024, as reported in SEC filings, driven by a $243.7M retained earnings swing, signaling a rapid transition from loss-making to highly profitable operations.
The balance sheet has transformed from a net deficit position to a fortress-like equity base, with total assets nearly doubling to $1.9B over ten quarters. The inflection in Q1 2025, when retained earnings turned positive, aligns with the AI-driven revenue surge, suggesting that profitability is now self-funding growth. This trajectory indicates a structural improvement in financial health, though the pace of asset growth may moderate as the company matures.
Astera Labs carries negligible debt, with D/E at 0.03 in Q1 2026 and zero debt in Q2 2026, as per balance sheet data, providing ample financial flexibility to fund R&D and potential M&A without interest burden.
The company's debt levels have been consistently minimal, with total debt never exceeding $58.2M, and the most recent quarter shows complete debt elimination. This conservative leverage, combined with a current ratio above 10, suggests that the company is not reliant on external financing, which is typical for a high-growth fabless semiconductor firm. The absence of debt reduces refinancing risk and positions the balance sheet to withstand potential downturns, though investors should note that the company may be under-leveraged, potentially leaving value on the table.
Astera Labs' asset base is dominated by current assets, with PPE net of $119.3M in Q2 2026, as reported in financial statements, representing only 6.3% of total assets, underscoring a capital-light, fabless business model.
The low PPE intensity is consistent with a fabless semiconductor company that outsources manufacturing, allowing it to scale without heavy fixed investment. Goodwill of $91.6M, which appeared in Q1 2026, likely stems from an acquisition, and while it is not yet impaired, investors should monitor for potential write-downs if the acquired technology underperforms. The asset mix suggests that the company's value lies in its intellectual property and working capital management rather than physical assets, which is typical for high-margin, design-centric firms.
Astera Labs' retained earnings swung from -$218.4M in Q1 2024 to $243.7M in Q2 2026, as per balance sheet data, a $462.1M turnaround that underscores the company's rapid transition to sustained profitability.
The dramatic improvement in retained earnings is a direct result of the AI-driven revenue surge, with net income turning positive in Q1 2025 and accelerating since. This equity build-up is primarily organic, reflecting strong earnings retention rather than external capital raises, which is a positive signal for shareholders. However, the company's stock-based compensation, which totaled $64M in Q2 2026, may dilute existing shareholders over time, and investors should adjust for this when assessing equity quality.
Astera Labs' current ratio stands at 10.05 in Q2 2026, as reported in financial statements, with cash of $111.5M, down from $421.1M in Q2 2024, indicating a strong liquidity position that can absorb operational shocks.
The current ratio has remained above 10 for the past ten quarters, reflecting a highly liquid balance sheet with minimal short-term obligations. The decline in cash from $696.1M in Q1 2024 to $111.5M in Q2 2026 is likely due to investments in working capital and acquisitions, but the company still holds sufficient cash to cover near-term liabilities. This liquidity provides a buffer against potential demand volatility, though the cash burn in Q2 2026, driven by a $143.5M working capital outflow, warrants monitoring to ensure it does not persist.
Astera Labs' balance sheet may be distorted by $91.6M in goodwill and significant stock-based compensation, as per recent filings, which could overstate asset quality and understate dilution, warranting careful adjustment by investors.
The sudden appearance of goodwill in Q1 2026 suggests an acquisition, and while it is not impaired, the risk of future write-downs exists if the acquired business fails to meet growth expectations. Additionally, the company's heavy use of stock-based compensation, which totaled $64M in Q2 2026, inflates equity but dilutes existing shareholders, making reported equity appear stronger than the true economic value. Investors should adjust for these items to assess the balance sheet's real strength, as headline numbers may be misleading.
Quick answers to the most common questions about buying ALAB stock.
As of 2025, Astera Labs, Inc. Common Stock (ALAB) had total assets of $1.53B including $1.36B in current assets.
Astera Labs, Inc. Common Stock (ALAB) carries total debt of $35.1M, offset by $1.19B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Astera Labs, Inc. Common Stock (ALAB) has total shareholders' equity (book value) of $1.36B ($7.59 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Astera Labs, Inc. Common Stock (ALAB) reported a current ratio of 10.24x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.